A Population-Based Survey of Drug Treatment Efficacy by the French National Committee for the Control of Arterial Hypertension

Jm, Mallion; L, Poggi

doi:10.1016/s0895-7061(98)00083-1

Cited by 5 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the general hypertensive population, patients' adherence to the prescribed treatment regimen becomes a key determinant of the success of blood pressure control (30). Several factors play a role in compliance with the lifestyle changes and antihypertensive drug(s) that may be needed to control hypertension effectively.…”

Section: Tolerability Compliance and Persistencementioning

confidence: 99%

Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection

et al. 2005

View full text Add to dashboard Cite

In the prevention and treatment of cardiovascular disease, pharmacological treatment strategies should have several aims: (i) in individuals without overt cardiovascular disease, but with risk factors such as hypertension and/or diabetes, pharmacotherapy should prevent or delay disease development; (ii) in patients who have already progressed to cardiovascular disease, pharmacotherapy should help either to prevent or regress target organ damage (TOD); and (iii) in patients with TOD, pharmacotherapy should prevent events. Any medication intended for long-term therapy also should be well tolerated. Inhibiting the renin-angiotensin system has proven a successful therapeutic strategy in cardiovascular and renal medicine. Angiotensin-converting enzyme (ACE) inhibitors have demonstrated important advantages over conventional agents such as beta-blockers and thiazide diuretics, and have become a relevant part of treatment for heart failure post-myocardial infarction, left ventricular dysfunction and renal disease. Tolerability concerns may prevent their use in some patients, however. Angiotensin AT1 receptor blockers (ARBs) provide a different form of blockade of the renin-angiotensin system and a growing body of evidence suggests that this alternative approach may confer additional cardiovascular protection for some patient subgroups. In addition, ARBs generally are better tolerated than ACE inhibitors, enhancing patient compliance and persistence with long-term therapy. Furthermore, evidence in favour of combining an ACE inhibitor and an ARB in certain circumstances is continuously growing.

show abstract

Section: Tolerability Compliance and Persistencementioning

confidence: 99%

Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection

et al. 2005

View full text Add to dashboard Cite

show abstract

“…On the basis of the NATPOL and PolSenior studies in Poland, almost 10.5 million people over 18 years of age suffer from HTN [3][4][5]. In most European countries, blood pressure (BP) control is not satisfactory, and recommended BP targets are achieved only in 9% of patients in the United Kingdom, 15% in Spain, 27% in France, and 29% in Germany [6][7][8][9]. In Poland, currently almost 26% of HTN-treated patients achieve the recommended BP values.…”

Section: Introductionmentioning

confidence: 99%

Education, cardiovascular risk factors and blood pressure control in hypertensive outpatients

Żylińska¹,

Kosior²

2018

Kardiol Pol

View full text Add to dashboard Cite

show abstract

“…Although seemingly simple to implement in most hypertension clinics, achieving target pressures in the hypertensive population remains a difficult issue. Importantly, adherence to the prescribed treatment regimen is a key determinant of the success of blood pressure control in most patient populations (10). Several known factors influence compliance with the antihypertensive lifestyle changes and drug therapy.…”

mentioning

confidence: 99%

More focus on therapeutic targets and improved tolerability in hypertension

Hedner¹,

Kjledsen²,

Oparil³

2008

Blood Pressure

View full text Add to dashboard Cite

A Population-Based Survey of Drug Treatment Efficacy by the French National Committee for the Control of Arterial Hypertension

Cited by 5 publications

References 3 publications

Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection

Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection

Education, cardiovascular risk factors and blood pressure control in hypertensive outpatients

More focus on therapeutic targets and improved tolerability in hypertension

Contact Info

Product

Resources

About